The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Abstract
BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS: In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 weeks. The study was expanded to include 123 additional patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 weeks (82 previously untreated patients) or 24 weeks (41 patients who had previous virologic failure with telaprevir or boceprevir plus peginterferon alfa-ribavirin). The primary end point was a sustained virologic response (an HCV RNA level of <25 IU per milliliter) at week 12 after the end of therapy. RESULTS: Overall, 211 patients received treatment. Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virologic response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of therapy. A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virologic response at week 12. High rates of sustained virologic response at week 12 were observed among patients with HCV subtypes 1a and 1b (98% and 100%, respectively) and those with CC and non-CC IL28B genotypes (93% and 98%, respectively), as well as among patients who received ribavirin and those who did not (94% and 98%, respectively). The most common adverse events were fatigue, headache, and nausea. CONCLUSIONS: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir. (Funded by Bristol-Myers Squibb and Pharmasset (Gilead); A1444040 ClinicalTrials.gov number, NCT01359644.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Self-citationGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Self-citationDiagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Self-citationTelaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationSchaff, Z., & Csmos, G. (1994) · Cited by 1,868
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Self-citationTelaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Self-citation
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Global distribution and prevalence of hepatitis C virus genotypes
Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E. (2015) · Hepatology · doi:10.1002/hep.27259 · Cited by 1,589
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationPetruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., & Cacciapuoti, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7824 · Cited by 864
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Self-citationABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Self-citationNelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., et al. (2015) · Hepatology · doi:10.1002/hep.27726 · Cited by 689
Self-citationOral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Self-citationInternational trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594
“Additionally, almost all HCV infections are now potentially curable, and treatment with direct-acting antiviral (DAA) therapy is increasingly accessible in the US.37 In Colombia in 2017, the Ministry of Health and Social Protection of Colombia began obtaining DAAs at an affordable price through the Pan American Health…”
BackgroundInfluentialNew Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Kim, I. H., Kisseleva, T., & Brenner, D. A. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000176 · Cited by 497
Poordad, F., Schiff, E. R., Vierling, J. M., Landis, C., Fontana, R. J., Yang, R., McPhee, F., Hughes, E. A., Noviello, S., & Swenson, E. S. (2016) · Hepatology · doi:10.1002/hep.28446 · Cited by 460
Self-citationWebster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
Self-citationSpearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
Negro, F., Forton, D., Craxì, A., Sulkowski, M. S., Feld, J. J., & Manns, M. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.035 · Cited by 361
Self-citationManns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
Self-citationHeart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Woolley, A. E., Singh, S. K., Goldberg, H. J., Mallidi, H. R., Givertz, M. M., Mehra, M. R., Coppolino, A., Kusztos, A. E., Johnson, M. E., Chen, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812406 · Cited by 335
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Bourlière, M., Bronowicki, J.-P., de Ledinghen, V., Hézode, C., Zoulim, F., Mathurin, P., Tran, A., Larrey, D. G., Ratziu, V., Alric, L., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70050-2 · Cited by 280
Self-citationMen with severe hemophilia in the United States: birth cohort analysis of a large national database
Mazepa, M. A., Monahan, P. E., Baker, J. R., Riske, B. K., & Soucie, J. M. (2016) · Blood · doi:10.1182/blood-2015-10-675140 · Cited by 117
Hepatitis C can be cured globally, but at what cost?
Hill, A., & Cooke, G. (2014) · Science · doi:10.1126/science.1257737 · Cited by 65
Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw266 · Cited by 19
Metadata
- Authors
- Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., Schwartz, H., Nelson, D. R., Everson, G. T., Eley, T., Wind-Rotolo, M., Huang, S.-P., Gao, M., Hernandez, D., McPhee, F., Sherman, D., Hindes, R., Symonds, W., Pasquinelli, C., & Grasela, D. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-16
- Volume
- 370
- Issue
- 3
- Pages
- 211-221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1980771473
- Cited by
- 1,190
- References
- 22
- FWCI
- 131.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.